Evidence map›Paper›PMID 22013105›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2012

Exenatide exerts a potent antiinflammatory effect.

Ajay Chaudhuri, Husam Ghanim, Mehul Vora, Chang Ling Sia, Kelly Korzeniewski, Sandeep Dhindsa, Antoine Makdissi, Paresh Dandona

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04122716 (Synergy Effect of the Appetite Hormone GLP-1), which is not on this map. Cited by 135 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 5 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04122716 phase4unknown statusstarted 2016, after this paper: background citation

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
PMID 23186644PMID 26132939PMID 26284720PMID 28049736PMID 30052921PMID 27295427PMID 27633186PMID 25287751PMID 23812094PMID 11234459PMID 22436841PMID 18663167other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 5 syntheses or guidelines pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Sitagliptin exerts an antinflammatory action.The Journal of clinical endocrinology and metabolism · 2012
    Trial
  18. Trial
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ajay ChaudhuriDivision of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, Buffalo, New York 14209, USA.
Husam Ghanim
Mehul Vora
Chang Ling Sia
Kelly Korzeniewski
Sandeep Dhindsa
Antoine Makdissi
Paresh Dandona
Kaleida Health · USUniversity at Buffalo, State University of New York · US

Funding

Inflammation in obesity: Modulation by Weight LossR01DK069805 · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2005 to 2005
$283k
NIDDK NIH HHS R01 DK069805NIDDK NIH HHS R01 DK075877
6 · The paper itself

Abstract

objectiveOur objective was to determine whether exenatide exerts an antiinflammatory effect. RESEARCH DESIGN AND

methodsTwenty-four patients were prospectively randomized to be injected sc with either exenatide 10 μg twice daily [n = 12; mean age = 56 ± 3 yr; mean body mass index = 39.8 ± 2 kg/m(2); mean glycosylated hemoglobin (HbA1c) = 8.6 ± 0.4%] or placebo twice daily (n = 12; mean age = 54 ± 4 yr; mean body mass index = 39.1 ± 1.6 kg/m(2); mean HbA1c = 8.5 ± 0.3%) for 12 wk. Fasting blood samples were obtained at 0, 3, 6, and 12 wk. Blood samples were also collected for up to 6 h after a single dose of exenatide (5 μg) or placebo.

resultsFasting blood glucose fell from 139 ± 17 to 110 ± 9 mg/dl, HbA1c from 8.6 ± 0.4 to 7.4 ± 0.5% (P < 0.05), and free fatty acids by 21 ± 5% from baseline (P < 0.05) with exenatide. There was no weight loss. There was a significant reduction in reactive oxygen species generation and nuclear factor-κB binding by 22 ± 9 and 26 ± 7%, respectively, and the mRNA expression of TNFα, IL-1β, JNK-1, TLR-2, TLR-4, and SOCS-3 in mononuclear cells by 31 ± 12, 22 ± 10, 20 ± 11, 22 ± 9, 16 ± 7, and 31 ± 10%, respectively (P < 0.05 for all) after 12 wk of exenatide. After a single injection of exenatide, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive oxygen species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression, 18 ± 7% in JNK-1 expression, 24 ± 12% in TLR-4 expression, and 23 ± 11% in SOCS-3 expression (P < 0.05 for all). The plasma concentrations of monocyte chemoattractant protein-1, matrix metalloproteinase-9, serum amyloid A, and IL-6 were suppressed after 12 wk exenatide treatment by 15 ± 7, 20 ± 11, 16 ± 7, and 22 ± 12%, respectively (P < 0.05 for all).

conclusionsExenatide exerts a rapid antiinflammatory effect at the cellular and molecular level. This may contribute to a potentially beneficial antiatherogenic effect. This effect was independent of weight loss.

Indexed as

Anti-Inflammatory AgentsBlood GlucoseDiabetes Mellitus, Type 2Drug Administration ScheduleExenatideFatty Acids, NonesterifiedHumansHypoglycemic AgentsInsulinMiddle AgedObesityPeptidesPlacebosReactive Oxygen SpeciesSingle-Blind MethodTime FactorsAnti-Inflammatory AgentsBlood GlucoseExenatideFatty Acids, NonesterifiedHypoglycemic AgentsInsulinPeptidesPlacebosReactive Oxygen SpeciesVenoms

Identifiers

PMID22013105
PMCPMC3251936
OpenAlexW2055611619

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.